FDA official quits after blocking Sarepta Gene therapy access

FDA's Vinay Prasad resigned after backlash over pausing Sarepta's Elevidys gene therapy, following deaths linked to treatment. Critics accused him of restricting access to a life-saving drug. Sarepta later resumed shipments for ambulatory patients only. Retail sentiment turned 'extremely bullish' on Stocktwits despite the stock's 87% YTD drop.